LIVE WEBINAR
Thursday, May 07 | 1pm ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording. ​

Many long-anticipated policy reforms will take effect this year, resulting in real commercial impacts for pharmaceutical manufacturers. As policy pressures intensify, specialty drug pricing is becoming a systemic access challenge, reflecting the combined influence of affordability, reimbursement models, competitive dynamics, and patient behavior. In the future, contracting, performance, and value demonstration will become increasingly critical to ensuring access. 

In this webinar, we’ll share insights on the state of patient access today from a survey of 250 high-level industry stakeholders. We’ll explore how brands are rethinking their market access strategies in response to these pressures, and developing AI and RWD capabilities to troubleshoot access challenges and generate more comprehensive evidence. Attendees will learn:

• How the IRA, PBM reform, DTC- and MFN-related models have driven strategy changes for pharma companies
• How rising price sensitivity is affecting patient access to high-cost specialty drugs 
• The impact of AI-enabled utilization management and prior authorization automation on access
• Areas of greatest opportunity for AI, real-world data and advanced analytics to improve patient access 

SPEAKERS

Hannah Baxter
Partner
The Dedham Group

Andrew Rouff
Senior Consultant
MMIT